Literature DB >> 12785011

Sustained tolerance to lipopolysaccharide after liver ischemia-reperfusion injury.

Lorrie A Langdale1, Osamu Kajikawa, Charles Frevert, H Denny Liggitt.   

Abstract

Liver ischemia-reperfusion injury (IR) would be expected to alter the capacity of previously ischemic as well as continuously perfused segments that are exposed to circulating inflammatory mediators to respond to a subsequent infectious insult. IR is reported to induce tolerance to subsequent endotoxin stimulation if the lipopolysaccharide (LPS) challenge is delayed until the late, neutrophil-mediated phase of reperfusion. Whether ischemic or perfused liver is differentially affected and whether LPS-tolerance may be overcome by increasing exposure is unknown. We hypothesized that late tolerance after IR reflects a refractory state in which the liver's expression of pro-inflammatory mediators in response to secondary LPS is limited. Precision-cut tissue culture methodology was used to investigate the capacity of rabbit liver to respond to a spectrum of LPS stimulation 24 h after partial IR. Slices from normal liver showed a dose-dependent response to LPS for tumor necrosis factor (TNF-alpha) expression. Slices from both previously ischemic and continuously perfused lobes retained dose responsiveness for TNF-alpha, although TNF-alpha was significantly decreased at high LPS concentrations compared with normal liver. Ischemic liver sustained this blunted response despite extended exposure to LPS, whereas perfused slices recovered responsiveness to high dose LPS with prolonged stimulation. IR induced interleukin-8 in both ischemic and perfused liver, but secondary LPS stimulation did not augment interleukin-8 expression. Hepatic IR induces a late tolerance to secondary LPS challenge in locally ischemic tissue that cannot be overcome by increasing LPS exposure. Nonischemic liver exposed to the systemic effects of IR injury, however, retains a capacity to respond to LPS with sufficient stimulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12785011     DOI: 10.1097/01.shk.0000055238.25446.64

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  6 in total

1.  Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies.

Authors:  Inge A M de Graaf; Peter Olinga; Marina H de Jager; Marjolijn T Merema; Ruben de Kanter; Esther G van de Kerkhof; Geny M M Groothuis
Journal:  Nat Protoc       Date:  2010-08-19       Impact factor: 13.491

2.  Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages.

Authors:  Sung Ho Park; Kyung-Hyun Park-Min; Janice Chen; Xiaoyu Hu; Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2011-05-22       Impact factor: 25.606

3.  Description of a Recovery Model in Rabbits for the Study of the Late Phase of Liver Ischemia-Reperfusion Injury.

Authors:  Athina G Mantelou; Argyro Zacharioudaki; George Pappas-Gogos; Apostolos Papalois; Alexandra Papoudou-Bai; Anna Goussia; Georgios K Glantzounis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

4.  Protective effects of tumor necrosis factor alpha antibody and ulinastatin on liver ischemic reperfusion in rats.

Authors:  Yan-Ling Yang; Ji-Peng Li; Xiao-Ping Xu; Ke-Feng Dou; Shu-Qiang Yue; Kai-Zong Li
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

5.  Suppressor of cytokine signaling expression with increasing severity of murine hepatic ischemia-reperfusion injury.

Authors:  Lorrie A Langdale; Vicki Hoagland; Whitney Benz; Kimberly J Riehle; Jean S Campbell; Denny H Liggitt; Nelson Fausto
Journal:  J Hepatol       Date:  2008-05-08       Impact factor: 25.083

6.  Hepatocellular heme oxygenase-1: a potential mechanism of erythropoietin-mediated protection after liver ischemia-reperfusion injury.

Authors:  Kimberly J Riehle; Vicki Hoagland; Whitney Benz; Jean S Campbell; Denny H Liggitt; Lorrie A Langdale
Journal:  Shock       Date:  2014-11       Impact factor: 3.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.